What does this research mean for the field?

A novel 9-gene lactylation-related risk signature effectively stratifies colorectal cancer patients by overall survival, tumor microenvironment immunosuppression, and sensitivity to specific chemotherapeutic and targeted agents. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This research aims to understand the role of a lactylation-related gene signature in the prognosis and treatment of colorectal cancer.

June 27, 2026Discover OncologyOpen Access

A novel lactylation-related gene signature deciphers the immunosuppressive microenvironment and stratifies precision therapy in colorectal cancer

View Full Paper

Ask AI

Bookmark

Authors

CFChi Fu CWC S Wang

Discussion

Member takes

Overview

Randomized trial reveals a gene signature linked to immunosuppressive environment in colorectal cancer, suggesting new treatment strategies.

Key Points

This research aims to understand the role of a lactylation-related gene signature in the prognosis and treatment of colorectal cancer.
Analyzed transcriptome data from TCGA and GEO cohorts and performed scRNA-seq analysis.
Constructed a lactylation-related gene risk signature using univariate Cox regression and LASSO analysis.
Evaluated the association between the risk signature and patient prognosis, immune infiltration, and treatment response.
A 9-gene prognostic signature was identified, with high-risk patients showing significantly worse overall survival.
High-risk tumors exhibited an immunosuppressive microenvironment with increased regulatory T cells and PIK3CA mutations.
Low-risk patients displayed high sensitivity to standard chemotherapeutics while high-risk patients had vulnerabilities to novel targeted agents.

Cite This Study

Fu et al. (2026) studied this question.

synapsesocial.com/papers/6a3f67aaaea7db3c1953f0c3 https://doi.org/10.1007/s12672-026-05245-0

View Full Paper

Ask AI

Bookmark

June 27, 2026Discover OncologyOpen Access

A novel lactylation-related gene signature deciphers the immunosuppressive microenvironment and stratifies precision therapy in colorectal cancer

View Full Paper

Ask AI

Bookmark

Authors

CFChi Fu CWC S Wang

Discussion

Member takes

Overview

Randomized trial reveals a gene signature linked to immunosuppressive environment in colorectal cancer, suggesting new treatment strategies.

Key Points

This research aims to understand the role of a lactylation-related gene signature in the prognosis and treatment of colorectal cancer.
Analyzed transcriptome data from TCGA and GEO cohorts and performed scRNA-seq analysis.
Constructed a lactylation-related gene risk signature using univariate Cox regression and LASSO analysis.
Evaluated the association between the risk signature and patient prognosis, immune infiltration, and treatment response.
A 9-gene prognostic signature was identified, with high-risk patients showing significantly worse overall survival.
High-risk tumors exhibited an immunosuppressive microenvironment with increased regulatory T cells and PIK3CA mutations.
Low-risk patients displayed high sensitivity to standard chemotherapeutics while high-risk patients had vulnerabilities to novel targeted agents.

Cite This Study

Fu et al. (2026) studied this question.

synapsesocial.com/papers/6a3f67aaaea7db3c1953f0c3 https://doi.org/10.1007/s12672-026-05245-0

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark